ArticleJournal of advanced research2025
Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers.
Article in Journal of advanced research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 14 citations in OpenAlex.
- Association of cardiovascular-kidney-metabolic syndrome with blinding eye diseases: insights from a UK Biobank cohort analysis.Eye (London, England) · 2026Article
- Rural-urban disparities in cardiovascular and other competing risk of death among cancer patients.Journal of advanced research · 2026Article
- Tumor histologic subtypes and stage impact the risk of cardiovascular diseases death in lung cancer patients after chemotherapy or radiotherapy: a population-based study.Translational cancer research · 2026Article
- ETS‑1/ETS‑2 transcription factors in CVD (Review).International journal of molecular medicine · 2026Review
- Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer.JAMA network open · 2026Article
- Cardiovascular Disease Mortality Patterns Among People With Cancer in New South Wales, Australia: A Population-Wide Data Linkage Study.Cancer medicine · 2026Article
- Post-treatment renal function deterioration following radiation therapy: implications for SABR in primary renal cell cancer.Frontiers in oncology · 2026Article
- Cardio-Oncology Risk Phenotypes in Cancer Patients Treated with Chemotherapy: A Data-Driven Analysis.Frontiers in cardiovascular medicine · 2026Article
- Chronic liver disease and cirrhosis mortality following surgery for colon or rectal cancer.Scientific reports · 2025Article
- Neighborhood Disadvantage and Cardiovascular Mortality Among Colorectal Cancer Survivors.Cancers · 2025Article
- Tumor behavior disparities in all-cause and cause-specific mortality among patients with central nervous system tumors.Scientific reports · 2025Article
- Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study.European journal of medical research · 2025Article
- Risk classification for non-cancer death in middle-aged cancer patients.Journal of advanced research · 2025Article
- Article
- Atherosclerosis as a cause of death in patients with cancer: a cohort study.Cardio-oncology (London, England) · 2025Article
- Cardiovascular Disease Mortality Risk among Long-term Survivors of Different Hodgkin Lymphoma Types.Reviews in cardiovascular medicine · 2025Article
- Cardiovascular mortality risk among small bowel adenocarcinoma patients: a population-based study.BMC public health · 2025Article
- Cardiovascular Disease and Other Competing Causes of Death in Older Kidney Cancer Patients.Reviews in cardiovascular medicine · 2025Article
- Association of cardiovascular disease on cancer: observational and mendelian randomization analyses.Scientific reports · 2024Observational
- Novel models by machine learning to predict the risk of cardiac disease-specific death in young patients with breast cancer.Discover oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPrevious studies on cardiovascular disease (CVD) death risk in cancer patients mostly focused on overall cancer, age subgroups and single cancers.
objectivesTo assess the CVD death risk in non-metastatic cancer patients at 21 cancer sites.
methodsA total of 1,672,561 non-metastatic cancer patients from Surveillance, Epidemiology, and End Results (SEER) datebase (1975-2018) were included in this population-based study, with a median follow-up of 12·7 years. The risk of CVD deaths was assessed using proportions, competing-risk regression, absolute excess risks (AERs), and standardized mortality ratios (SMRs).
resultsIn patients with localized cancers, the proportion of CVD death and cumulative mortality from CVD in the high-competing risk group (14 of 21 unique cancers) surpassed that of primary neoplasm after cancer diagnosis. The SMRs and AERs of CVD were found higher in patients with non-metastatic cancer than the general US population (SMR 1·96 [95 %CI, 1·95-1·97]-19·85[95 %CI, 16·69-23·44]; AER 5·77-210·48), heart disease (SMR 1·94[95 %CI, 1·93-1·95]-19·25[95 %CI, 15·76-23·29]; AER 4·36-159·10) and cerebrovascular disease (SMR 2·05[95 %CI, 2·02-2·08]-24·71[95 %CI, 16·28-35·96]; AER 1·01-37·44) deaths. In the high-competing risk group, CVD-related SMR in patients with localized stage cancer increased with survival time but followed a reverse-dipper pattern in the low-competing risk group (7 of 21 cancers). The high-competing risk group had higher CVD-related death risks than the low-competing risk group.
conclusionThe CVD death risk in patients with non-metastatic cancer varied by cancer stage, site and survival time. The risk of CVD mortality is higher in 14 out of 21 localized cancers (high-competing cancers). Targeted strategies for CVD management in non-metastatic cancer patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.